Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$50.77
-5.8%		$55.57
$13.86
▼
$72.36
$1.60B0.71489,961 shs779,576 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$73.36
-5.6%		$74.30
$35.64
▼
$80.97
$6.89B0.24762,110 shs830,942 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$89.32
-2.3%		$102.05
$63.23
▼
$130.00
$5.93B0.49616,508 shs739,007 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$89.93
-4.9%		$96.79
$14.89
▼
$115.51
$6.26B-0.34793,730 shs1.99 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-5.84%-6.52%-13.12%-14.93%+142.34%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-5.63%-1.03%-6.23%+0.71%+99.89%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-2.27%-8.27%-7.65%-23.84%+21.33%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-4.89%-3.87%-12.19%+3.81%+477.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$50.77
-5.8%		$55.57
$13.86
▼
$72.36
$1.60B0.71489,961 shs779,576 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$73.36
-5.6%		$74.30
$35.64
▼
$80.97
$6.89B0.24762,110 shs830,942 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$89.32
-2.3%		$102.05
$63.23
▼
$130.00
$5.93B0.49616,508 shs739,007 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$89.93
-4.9%		$96.79
$14.89
▼
$115.51
$6.26B-0.34793,730 shs1.99 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-5.84%-6.52%-13.12%-14.93%+142.34%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-5.63%-1.03%-6.23%+0.71%+99.89%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-2.27%-8.27%-7.65%-23.84%+21.33%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-4.89%-3.87%-12.19%+3.81%+477.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.69
Moderate Buy$79.1555.91% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.73
Moderate Buy$87.7819.65% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3153.73% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$133.0047.89% Upside

Current Analyst Ratings Breakdown

Latest ANAB, CGON, ORKA, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$90.00 ➝ $81.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
9/22/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/3/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
8/31/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$78.00
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$137.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$75.00 ➝ $70.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold$70.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M6.41N/AN/A$1.34 per share37.89
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,609.56N/AN/A$9.33 per share7.86
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M11.12$0.05 per share1,792.69$6.12 per share14.59
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M$5.379.4520.81N/A82.37%112.00%2.20%11/3/2026 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%11/3/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)

Latest ANAB, CGON, ORKA, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/21/2026Q2 2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$0.4650$5.11+$5.5750$5.11$14.06 million$27.49 million
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10429.61 million20.28 millionOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
14288.64 million84.39 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
43364.93 million59.53 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
6866.21 million50.66 millionN/A

Recent News About These Companies

What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
September 23 at 11:52 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/oruka-therapeutics-orka-phase-2a-001607605.html
Oruka Therapeutics Announces Positive Week 28 Results From EVERLAST-A Phase 2a Trial Of ORKA-001
September 23 at 6:51 PM  |  marketscreener.comM
Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001
September 23 at 6:51 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oruka-shares-fall-despite-deepening-182824182.html
Oruka Therapeutics (NASDAQ:ORKA) Shares Down 7.4% - Here's Why
September 23 at 2:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-oruka-therapeutics-nasdaq-orka-shares-down-74-heres-why-2026-09-23/
Oruka's ORKA-001 shows deepening psoriasis response at week 28
September 23 at 1:50 PM  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Orukas+ORKA-001+shows+deepening+psoriasis+response+at+week+28/27093218.html
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
September 23 at 1:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/oruka-therapeutics-shares-fall-5-125237843.html
Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28
September 23 at 1:50 PM  |  marketscreener.comM
Oruka falls after updating mid-stage trial data for plaque psoriasis therapy
September 23 at 1:50 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4646209-oruka-posts-trial-data-plaque-psoriasis-drug
Oruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down
September 23 at 8:49 AM  |  rttnews.comhttps://www.rttnews.com/3693262/oruka-reports-positive-week-28-results-for-orka-001-in-plaque-psoriasis-stock-down.aspx
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
September 23 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367325/0/en/oruka-therapeutics-announces-positive-week-28-data-for-orka-001-from-the-ongoing-everlast-a-trial-showing-deepening-of-responses-without-additional-dosing.html
352,824 Shares in Oruka Therapeutics, Inc. $ORKA Bought by Bank of America Corp DE
September 23 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-352824-shares-in-oruka-therapeutics-inc-orka-bought-by-bank-of-america-corp-de-2026-09-23/
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $51,034.75 in Stock
September 22 at 4:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-orka-insider-buying-and-selling-2026-09-22/
Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing
September 22 at 1:07 AM  |  marketscreener.comM
Arjun Agarwal Sells 533 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 21 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-arjun-agarwal-sells-533-shares-of-oruka-therapeutics-nasdaq-orka-stock-2026-09-21/
Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $234,680.92 in Stock
September 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31031463
Arjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029295
Joana Goncalves Sells 7,947 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31029294
Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 Shares
September 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-orka-insider-buying-and-selling-2026-09-16/
Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-svp-arjun-agarwal-sells-560-shares-of-stock-2026-09-15/
Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-lawrence-otto-klein-sells-2452-shares-of-oruka-therapeutics-nasdaq-orka-stock-2026-09-15/
Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-oruka-therapeutics-nasdaq-orka-insider-joana-goncalves-sells-7947-shares-of-stock-2026-09-15/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$50.77 -3.15 (-5.84%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$50.82 +0.04 (+0.09%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$73.36 -4.38 (-5.63%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$73.36 0.00 (-0.01%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$89.32 -2.07 (-2.27%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$89.14 -0.17 (-0.20%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$89.93 -4.62 (-4.89%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$89.39 -0.54 (-0.60%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas